



Advances in Thoracic Carcinoma and Translational Research

Guest Editors:

Dr. Jiangyong Yu

Dr. Jun Zhao

Dr. Jie Ma

Dr. Jia Zhong

Deadline for manuscript
submissions:

closed (15 November 2023)

Message from the Guest Editors

Dear Colleagues,

This Special Issue will focus on the significant progress in the treatments, biomarkers and translational research of thoracic carcinoma in recent years, including original articles and reviews of the new standard of care for lung cancer as well as rarer cancers such as mesothelioma and thymic neoplasms. Just as important are the challenges that remain to be overcome. In this issue, we will focus on the diagnosis and therapy of patients with lung cancer, advances in targeted therapy, immunotherapy and also ADC drugs in patients with lung cancer, and the new diagnosis strategies and biomarkers in patients with lung cancer and other thoracic carcinomas, the optimization of first- and second-line treatment for patients with small cell lung cancer, translational researches in lung cancer and other thoracic carcinomas, and the selection of chemotherapy or immunotherapy for patients with mesothelioma and thymic neoplasms. We will also address areas of ongoing research including immune-related toxicities and attempts to overcome resistance to chemotherapy and immunotherapy.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)